Peter M Izmirly, Mimi Y Kim, Philip M Carlucci, Katherine Preisinger, Brooke Z Cohen, Kristina Deonaraine, Devyn Zaminski, Maria Dall'Era, Kenneth Kalunian, Andrea Fava, H Michael Belmont, Ming Wu, Chaim Putterman, Jennifer Anolik, Jennifer L Barnas, Betty Diamond, Anne Davidson, David Wofsy, Diane Kamen, Judith A James, Joel M Guthridge, William Apruzzese, Deepak A Rao, Michael H Weisman, Michelle Petri, Jill Buyon, Richard Furie
BACKGROUND: Leveraging the Accelerating Medicines Partnership (AMP) Lupus Nephritis (LN) dataset, we evaluated longitudinal patterns, rates, and predictors of response to standard-of-care therapy in patients with lupus nephritis. METHODS: Patients from US academic medical centers with class III, IV, and/or V LN and a baseline urine protein/creatinine (UPCR) ratio ≥ 1.0 (n = 180) were eligible for this analysis. Complete response (CR) required the following: (1) UPCR < 0...
February 20, 2024: Arthritis Research & Therapy